Aldurazyme, generically known as laronidase, is a therapeutic enzyme specifically designed for the treatment of Mucopolysaccharidosis I (MPS I), a rare and inherited lysosomal storage disorder. This condition is caused by the body's inability to produce enough of a specific enzyme required to break down glycosaminoglycans (GAGs), leading to their accumulation in various tissues and organs, which can result in widespread damage and dysfunction. Aldurazyme works by supplementing the deficient enzyme, thereby helping to reduce the buildup of GAGs and alleviate the symptoms associated with MPS I. Administered through intravenous infusion, Aldurazyme is a form of enzyme replacement therapy that has been a significant advancement in the management of MPS I, offering patients the potential for improved quality of life and reduced disease progression.